Table 3 |
|||
|
Disease and demographic characteristics of patients based on the status of protective antibody levels at 1 |
|||
|
Patients with protective antibody levels at 1.5 years of follow-up (n = 132) |
Patients without protective antibody levels at 1.5 years of follow-up (n = 170) |
P value |
|
|
|
|||
|
Age (years); mean (SD) (range) |
51.7 (13) (24-79) |
60.1 (11) (30-85) |
P < 0.001a |
|
|
|||
|
Patient age ≥65 years (%) |
16% |
37% |
P < 0.001b |
|
|
|||
|
Gender (female %) |
58% |
72% |
P = 0.01b |
|
|
|||
|
Disease duration (years); mean (SD) (range) |
13.8 (10) (0-45) |
16.7 (11) (0-46) |
P = 0.039a |
|
|
|||
|
DAS at vaccination; mean (SD) (range) |
3.0 (1.3) (0-5.6) |
3.5 (1) (0-6.4) |
P = 0.001a |
|
|
|||
|
HAQ at vaccination; mean (SD) (range) |
0.6 (0.5) (0-2) |
0.9 (0.7) (0-3) |
P < 0.001a |
|
|
|||
|
RA (yes, %) |
38/62 |
66/34 |
P < 0.001b |
|
|
|||
|
Ongoing MTX (yes, %) |
44% |
61% |
P < 0.001b |
|
|
|||
|
Ongoing anti-TNF treatment (yes, %) |
60% |
72% |
P = 0.029b |
|
|
|||
|
Positive antibody response for 6B and 23F at 4 to 6 weeks of follow-up (yes, %) |
37.1% |
25% |
P = 0.027b |
|
|
|||
|
Protective antibody levels for both 6B and 23F serotypes at vaccination (%) |
72% |
20.6% |
P < 0.001b |
|
|
|||
|
aMann-Whitney U test. bχ2 test. |
|||
|
Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013 15:R1 doi:10.1186/ar4127 |
|||
